Effect and Safety of Helicobacter pylori Eradication Treatment Based on Molecular Pathologic Antibiotic Resistance in Chinese Elderly People
Chun Gao,Yan-Hua Fan
DOI: https://doi.org/10.2147/IDR.S371113
2022-06-22
Infection and Drug Resistance
Abstract:Chun Gao, Yan-Hua Fan Department of Gastroenterology, China-Japan Friendship Hospital, Beijing, 100029, People's Republic of China Correspondence: Yan-Hua Fan, Department of Gastroenterology, China-Japan Friendship Hospital, No. 2 Yinghua East Road, Beijing, 100029, People's Republic of China, Tel/Fax +86 10-84205503, Email Background: The elderly people generally have poor tolerance to drugs and an increased risk of adverse effects. Our study was designed to determine the effect and safety of Helicobacter pylori ( H. pylori ) eradication treatment based on molecular pathologic antibiotic resistance in Chinese elderly people over the age of 60 years. Methods: A total of 364 people were retrospectively analyzed, including 113 older people over 60 and 251 young and middle-aged people in the age of 20– 59 years. Real-time PCR detection and conventional PCR and sequencing method were used for drug susceptibility testing. As the main outcome measure, the eradication rates (ERs) with their 95% confidence intervals (CIs) were analyzed by intention to treat (ITT) and per protocol (PP). For the safety of therapy, adverse events were analyzed. Results: For the total people, the resistance rates to clarithromycin (CLR), amoxicillin (AMX), fluoroquinolone (FLQ) and tetracycline (TET) were 65.06%, 7.54%, 61.39% and 20.37%, respectively. After they were divided into two groups, the resistance rates were 62.39% (CLR), 9.09% (AMX), 69.64% (FLQ) and 22.45% (TET) in the 113 older people over 60, and 66.26%, 6.85%, 57.66% and 19.47% in the 251 young and middle-aged people in 20– 59. By the ITT analysis, the ERs were 92.04% (95% CI, 86.97– 97.10%, n=113) in the older people and 92.43% (95% CI, 89.14– 95.73%, n=251) in the young and middle-aged people. By the PP analysis, the ERs were 96.30% (95% CI, 92.68– 99.92%, n=108) and 94.69% (95% CI, 91.87– 97.52%, n=245), respectively. No significant differences were shown both in the ITT analysis (P=0.896) and in the PP analysis (P=0.517). The three most common adverse events were black stool, dysgeusia and diarrhea, and no serious adverse event was reported. Conclusion: H. pylori eradication treatment based on molecular pathologic antibiotic resistance showed good effect and safety in Chinese elderly people. Keywords: Helicobacter pylori , antibiotic resistance, elderly people, molecular pathology, eradication treatment Helicobacter pylori ( H. pylori ) infection has been regarded as the most important cause of chronic gastritis and it can lead to chronic active gastritis in almost all the people infected with H. pylori . 1 According to the Kyoto global consensus report on H. pylori gastritis, H. pylori can transmit easily between people and H. pylori gastritis has been defined as an infectious disease. 1,2 Moreover, H. pylori infection has been identified as the main cause of a number of upper gastrointestinal diseases, including gastric ulcer, duodenal ulcer, gastric adenocarcinoma and gastric MALT (mucosa associated lymphoid tissue) lymphomas. 3,4 Therefore, all H. pylori -infected people should be subjected to the eradication treatment, which can help to heal peptic ulcer, achieve remission of MALT lymphomas, and decrease the risk of gastric cancer. 5–7 For H. pylori treatment, clarithromycin-based triple therapy (proton pump inhibitor/ PPI + clarithromycin + amoxicillin/metronidazole) or bismuth quadruple therapy (PPI/H2RA + bismuth + metronidazole + tetracycline) are the recommended primary therapies in the United States, and bismuth-containing quadruple therapy (PPI + bismuth + two antibiotics) is the main recommended empirical therapy in China. 1,8 The increasing prevalence of antibiotic resistance is our main concern in treatment of H. pylori infection, which can lead to significant eradication failure. 9,10 In China, the resistance rates to clarithromycin, metronidazole, and levofloxacin, are already high. One study from Nanjing showed that the H. pylori resistance rates to clarithromycin, levofloxacin and metronidazole were 47.03%, 33.59% and 80.76%, respectively. 11 Ideally, treatment regimens of H. pylori eradication should be determined by the results of drug susceptibility testing. According to the recommendations by multiple authoritative guides, only regimens with eradication rates of ≥90% can be used for empirical treatment. 1,2,12,13 H. pylori culture and molecular biology methods can be used for susceptibility testing. However, culture has a high specificity and a relatively low sensitivity, and certain technique is required. 1,14 With the rapid -Abstract Truncated-
pharmacology & pharmacy,infectious diseases